All In Biotech

NDA 215499 · Viiv Hlthcare

Apretude

Cabotegravir · Intramuscular

Breakthrough therapyPriority review

Last checked: Nov 19, 2026Latest source record: Apr 11, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Dec 20, 2021

Approved uses

2

Original approval plus efficacy supplements

Registered trials

97

26 Phase 3, 19 recruiting

FAERS reports

8,201

1,642 serious, 105 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISK OF DRUG RESISTANCE WITH USE OF APRETUDE FOR HIV-1 PRE‑EXPOSURE PROPHYLAXIS (PrEP) IN UNDIAGNOSED HIV-1 INFECTION Individuals must be tested for HIV-1 infection prior to initiating APRETUDE or oral cabotegravir, and with each subsequent injection of APRETUDE, using a test approved or cleared by the FDA for the diagnosis of acute or primary HIV-1 infection. Drug-resistant HIV-1 variants have been identified with use of APRETUDE by individuals with undiagnosed HIV-1 infection. Do not initiate APRETUDE for HIV-1 PrEP unless negative infection status is confirmed. Individuals who acquire HIV-1 while receiving APRETUDE for PrEP must transition to a complete HIV-1 treatment regimen [see Dosage and Administration ( 2.2 ), Contraindications ( 4 ), Warnings and Precautions ( 5.1 )] . WARNING: RISK OF DRUG RESISTANCE WITH USE OF APRETUDE FOR HIV-1 PRE-EXPOSURE PROPHYLAXIS (PrEP) IN...

What it is approved for

From the label in effect Apr 11, 2025.

APRETUDE is indicated for pre‑exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents weighing at least 35 kg who are at risk for HIV-1 acquisition. Individuals must have a negative HIV-1 test prior to initiating APRETUDE (with or without an oral lead-in with oral cabotegravir) for HIV-1 PrEP [see Dosage and Administration ( 2.2 , 2.4 ), Contraindications ( 4 ), Warnings and Precautions ( 5.1 )] . APRETUDE is an HIV-1 integrase strand transfer inhibitor (INSTI) indicated for PrEP to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents weighing at least 35 kg who are at risk for HIV-1 acquisition. Individuals must have a negative HIV-1 test prior to initiating APRETUDE (with or without an oral lead-in with oral cabotegravir) for HIV-1 PrEP. ( 1 )

Mechanism: Cabotegravir is an HIV-1 antiretroviral drug [see Microbiology ( 12.4 )] in a long-acting formulation.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 20, 2024 Supplement 8 · Efficacy LetterLabel
  • Dec 20, 2021 Original approval · Type 5 - New Formulation or New Manufacturer · priority review Breakthrough therapyLabelLetterReview
1 products under this application
  • APRETUDE · CABOTEGRAVIR 600MG/3ML (200MG/ML) · SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Cabotegravir" as an intervention, any sponsor and status, largest first.

All 97 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • product dose omission issue1,128
  • off label use1,050
  • injection site pain943
  • viral load increased434
  • pain414
  • virologic failure270
  • pyrexia259
  • inappropriate schedule of product administration257
  • product use in unapproved therapeutic environment254
  • pathogen resistance251
  • product complaint240
  • drug ineffective236

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20162
201716
20187
201922
202038
2021253
2022997
20231,934
20242,656
20251,752
2026524

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Apretude (Cabotegravir)

2024 spending

$12.8M

Beneficiaries

996

3,358 claims

Per beneficiary

$12,875

$1,270.68 per unit

View as table
YearSpending
2020$0
2021$0
2022$2,684,050
2023$10,681,954
2024$12,823,732

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 117 on PubMed

Sponsor: GSK

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.